Feasibility assessment of the newest domestic anthelmintics development taking into account the existing drug range

Abstract

The development of high quality and affordable medicines inUkraineis an important area of the work of modern pharmacy within the import substitution policy. Aim. To determine the feasibility of developing a domestic drug for the treatment of helminthiases of the digestive system by evaluating the existing range of anthelmintic drugs presented on the pharmaceutical market ofUkraine. Results. Analysis of the available anthelmintic medicines range as of February 5, 2020, according to the data of the State Register of Medicines of Ukraine, showed that drugs of Р02В group (medicines used trematodoses for trematodoses treatment) are absent on the pharmaceutical market of Ukraine, and the available medicines are presented exclusively by monopreparations. The vast majority of drugs are made on the basis of albendazole and pyrantel substances, while the share of the drugs are produced on the basis of mebendazole, piperazine, and levamisole is much smaller. There are some discrepancies in determining the manufacturer of the medicinal product. Thus, the applicant producers are dominated by representatives of theUnited Kingdom,France andHungary, and the actual producers are those ofFrance,India andRomania. At the same time, the distribution of drugs both by manufacturers-applicants and by actual manufacturers corresponds to the preference for foreign drugs, while domestic manufacturers offer fewer anthelminthic drugs. Tablets and oral suspensions dominate among the presented dosage forms of anthelmintic drugs. Conclusions. According to the results of the market analysis of drugs for helminthiases treatment, it can be argued that the existing range does not fully meet the needs of the population of Ukraine for anthelmintic agents. It is advisable to develop the newest domestic anthelmintic drugs based on those substances that are included in the list of drugs of choice of the current protocols for helminthiases treatment. Particularly noteworthy is the complete absence of the P02B group drugs at the domestic pharmaceutical market, which indicates the urgency of the development of modern domestic anthelmintic drugs on the basis of appropriate substances. It is rational to combine several substances in order to obtain a wide range of pharmacological activity and synergies of substances, because today’s pharmaceutical market is represented exclusively by monotherapies.